IHP Therapeutics — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

IHP Therapeutics is a private, pre-revenue biotech founded in 2018 and headquartered in San Carlos, California. The company is singularly focused on advancing IHP-102, a novel dual P-selectin and complement inhibitor, as a potential at-home rescue therapeutic for acute pain crises in sickle cell disease (SCD). This approach targets two key drivers of vaso-occlusion and aims to reduce both symptoms and long-term organ damage. With a lean team and expert advisors, IHP is positioning itself to address a significant unmet need by shifting SCD crisis management away from overburdened emergency healthcare systems.

HematologyOncology

Technology Platform

Dual P-selectin and complement inhibition platform for treating vaso-occlusion.

Opportunities

The primary opportunity is to create the first self-administered rescue therapy for sickle cell pain crises, shifting care from the hospital to the home.

This could empower patients, significantly reduce high-cost hospitalizations, and potentially modify disease progression by preventing tissue damage.

The growing focus and investment in sickle cell disease create a favorable environment for innovation.

Risk Factors

Key risks include the unproven clinical efficacy and safety of the novel dual-inhibition mechanism, significant technical challenges in formulating a drug for safe and effective at-home self-administration, and increasing competition in the sickle cell disease therapeutic landscape.

The company's single-asset, pre-revenue status also creates high financial dependency on future fundraising.

Competitive Landscape

Competition includes crizanlizumab (Novartis), an approved IV-infused P-selectin inhibitor for VOC reduction, and other investigational therapies targeting adhesion or inflammation. IHP-102's primary differentiation is its dual mechanism and intended at-home rescue use case, a niche not currently addressed by other therapies which are primarily for chronic prevention or require clinical administration.

More companies in Small Molecule Drugs →More companies in United States →